+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Immunotherapy Drugs Market Research Report by Type (Cancer Vaccines, Checkpoint Inhibitors, and Immunomodulators), End-user, Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5336734
  • Report
  • April 2022
  • Region: United States
  • 104 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Cellectis
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
The United States Cancer Immunotherapy Drugs Market size was estimated at USD 34.37 billion in 2021, USD 40.77 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 14.91% to reach USD 79.16 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Cancer Immunotherapy Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators, and Monoclonal Antibodies.
  • Based on End-user, the market was studied across Hospitals & Clinics.
  • Based on Application, the market was studied across Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Immunotherapy Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Cancer Immunotherapy Drugs Market, including Amgen Inc., AstraZeneca plc, Atara Biotherapeutics, Inc., Bayer AG, Bluebird bio, Inc., Bristol-Myers Squibb, Celldex Therapeutics, Cellectis, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Janssen Global Services, LLC, Juno Therapeutics, Merck & Co., Inc., NewLink Genetics Corporation, Novartis AG, Pfizer Inc., and Ziopharm Oncology, Inc..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Cancer Immunotherapy Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Cancer Immunotherapy Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Cancer Immunotherapy Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Cancer Immunotherapy Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Cancer Immunotherapy Drugs Market?
6. What is the market share of the leading vendors in the United States Cancer Immunotherapy Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Cancer Immunotherapy Drugs Market?
Frequently Asked Questions about the U.S. Cancer Immunotherapy Drugs Market

What is the estimated value of the U.S. Cancer Immunotherapy Drugs Market?

The U.S. Cancer Immunotherapy Drugs Market was estimated to be valued at $34.4 Billion in 2021.

What is the growth rate of the U.S. Cancer Immunotherapy Drugs Market?

The growth rate of the U.S. Cancer Immunotherapy Drugs Market is 14.9%, with an estimated value of $79.2 Billion by 2027.

What is the forecasted size of the U.S. Cancer Immunotherapy Drugs Market?

The U.S. Cancer Immunotherapy Drugs Market is estimated to be worth $79.2 Billion by 2027.

Who are the key companies in the U.S. Cancer Immunotherapy Drugs Market?

Key companies in the U.S. Cancer Immunotherapy Drugs Market include Amgen Inc., AstraZeneca plc, Atara Biotherapeutics, Inc., Bayer AG, Bluebird bio, Inc., Bristol, Myers Squibb, Celldex Therapeutics and ELI Lilly and Company.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Cellectis
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Cancer Immunotherapy Drugs Market, by Type
6.1. Introduction
6.2. Cancer Vaccines
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Monoclonal Antibodies
7. Cancer Immunotherapy Drugs Market, by End-user
7.1. Introduction
7.2. Hospitals & Clinics
8. Cancer Immunotherapy Drugs Market, by Application
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Head and Neck Cancer
8.5. Lung Cancer
8.6. Melanoma
8.7. Prostate Cancer
9. California Cancer Immunotherapy Drugs Market10. Florida Cancer Immunotherapy Drugs Market11. Illinois Cancer Immunotherapy Drugs Market12. New York Cancer Immunotherapy Drugs Market13. Ohio Cancer Immunotherapy Drugs Market14. Pennsylvania Cancer Immunotherapy Drugs Market15. Texas Cancer Immunotherapy Drugs Market
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Amgen Inc.
17.2. AstraZeneca plc
17.3. Atara Biotherapeutics, Inc.
17.4. Bayer AG
17.5. Bluebird bio, Inc.
17.6. Bristol-Myers Squibb
17.7. Celldex Therapeutics
17.8. Cellectis
17.9. ELI Lilly and Company
17.10. F. Hoffmann-La Roche Ltd
17.11. Gilead Sciences, Inc.
17.12. GlaxoSmithKline plc
17.13. Incyte Corporation
17.14. Janssen Global Services, LLC
17.15. Juno Therapeutics
17.16. Merck & Co., Inc.
17.17. NewLink Genetics Corporation
17.18. Novartis AG
17.19. Pfizer Inc.
17.20. Ziopharm Oncology, Inc.
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: DYNAMICS
FIGURE 2. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 3. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2027
FIGURE 5. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2019-2027 (USD BILLION)
FIGURE 6. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 7. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2019-2027 (USD BILLION)
FIGURE 8. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 9. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, 2019-2027 (USD BILLION)
FIGURE 10. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 11. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2019-2027 (USD BILLION)
FIGURE 12. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 14. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (USD BILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2027
FIGURE 16. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, 2019-2027 (USD BILLION)
FIGURE 17. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 18. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 19. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2027
FIGURE 21. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2019-2027 (USD BILLION)
FIGURE 22. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 23. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, 2019-2027 (USD BILLION)
FIGURE 24. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 25. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, 2019-2027 (USD BILLION)
FIGURE 26. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 27. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2019-2027 (USD BILLION)
FIGURE 28. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 29. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2019-2027 (USD BILLION)
FIGURE 30. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 31. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, 2019-2027 (USD BILLION)
FIGURE 32. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 33. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 34. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 35. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 4. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY STATE, 2019-2027 (USD BILLION)
TABLE 5. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2019-2027 (USD BILLION)
TABLE 9. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 10. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 13. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 14. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY STATE, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: SCORES
TABLE 18. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: BUSINESS STRATEGY
TABLE 19. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: PRODUCT SATISFACTION
TABLE 20. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: RANKING
TABLE 21. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 22. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: MERGER & ACQUISITION
TABLE 23. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 24. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 25. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: INVESTMENT & FUNDING
TABLE 26. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 27. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • AstraZeneca plc
  • Atara Biotherapeutics, Inc.
  • Bayer AG
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb
  • Celldex Therapeutics
  • Cellectis
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Janssen Global Services, LLC
  • Juno Therapeutics
  • Merck & Co., Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Pfizer Inc.
  • Ziopharm Oncology, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...